{
    "organizations": [],
    "uuid": "3dffb32c28d87df50fb9505fbd21659cad7390c5",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/idUSL8N1RQ18M",
    "ord_in_thread": 0,
    "title": "BRIEF-WSE Admits To Trade Shares Of OncoArendi Therapeutics",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 13 (Reuters) - ONCOARENDI THERAPEUTICS SA ( IPO-ORT.WA )\n* ON THURSDAY WARSAW STOCK EXCHANGE (WSE) ADMITTED THE COMPANYâ€™S SERIES A, B, C, D AND F SHARES TO TRADE AS OF APRIL 12\n* IT HAS ALSO ADMITTED TO TRADE 2.0 MLN OF RIGHTS TO SERIES F SHARES AS OF APRIL 12\n* EARLIER IN MARCH, ONCOARENDI THERAPEUTICS SET THE MAXIMUM ISSUE PRICE IN THE IPO AT 33 ZLOTY PER SHARE\nSource text: [ bit.ly/2GU5Gde ]\nFurther company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-04-13T16:26:00.000+03:00",
    "crawled": "2018-04-14T13:42:14.106+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "oncoarendi",
        "therapeutic",
        "sa",
        "thursday",
        "warsaw",
        "stock",
        "exchange",
        "wse",
        "admitted",
        "company",
        "series",
        "b",
        "c",
        "f",
        "share",
        "trade",
        "april",
        "also",
        "admitted",
        "trade",
        "mln",
        "right",
        "series",
        "f",
        "share",
        "april",
        "earlier",
        "march",
        "oncoarendi",
        "therapeutic",
        "set",
        "maximum",
        "issue",
        "price",
        "ipo",
        "zloty",
        "per",
        "share",
        "source",
        "text",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}